NCT06948929 · RECRUITING
Synbiotic Formula (SCV09) in Alzheimer's Disease Patients
This pilot study is testing a synbiotic supplement called SCV09, which combines probiotics and prebiotics, in people already diagnosed with Alzheimer's disease. The goal is to see whether it improves dementia-related behaviors and is safe to use. Phase NA means this is a small exploratory study designed to gather early data before a larger, more rigorous trial. Details beyond the basics are limited so far.
You may qualify if
- Individuals aged between 60-85 with a clinical diagnosis of Alzheimer's disease
- Hong Kong version of Montreal Cognitive Assessment (HK-MoCA) score of ≤20
- Neuropsychiatric Inventory-Questionnaire (NPI-12) ≥10
- Stable medication history for Alzheimer's disease within the past 4 weeks
- Have been taken care by a responsible caregiver who could assist the patient in taking the study products, collecting stool samples and attending the clinical follow-up •-Able to provide informed consent
You're excluded if
- Concomitant Parkinson's disease and other neurodegenerative conditions affecting activities of daily living
- History of stroke
- History of severe organ failure (including decompensated cirrhosis), renal failure on dialysis, suffering from human immunodeficiency virus infection
- Confirmed active malignancy
- Known operations involving small intestines and large intestines; or history of appendectomy, hysterectomy, and cholecystectomy in last 6 months
- Use of anti-psychotics, antidepressants or sedatives, unless on a stable dose in the last 3 months
- Inability to receive oral fluids
- Use of antibiotics, probiotics or prebiotics in the last 2 weeks
- Intolerance to probiotics or lactose
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-09-03